drugset / Trial / NCT06998407
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-023 is an oral medication that inhibits cyclin-dependent kinase 4 (CDK4).
Timeline
- Start
- 2025-08-20
- Primary completion
- 2028-08
- Completion
- 2030-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AVZO-021 | Unknown | — | Oral |
| Subject | AVZO-023 | Unknown | — | Oral |
| Subject | Fulvestrant | Small molecule | — | — |
| Subject | Letrozole | Other / unclassified | — | Oral |